文章摘要
朱淑敏,马 进,耿玉兰,代丽丽,赵小洁,魏从真,刘金锋.血清OPN、Wip1、HSP90α与晚期非小细胞肺癌患者一线化疗敏感性和预后的关系[J].,2023,(24):4740-4745
血清OPN、Wip1、HSP90α与晚期非小细胞肺癌患者一线化疗敏感性和预后的关系
Relationship between Serum OPN, Wip1, HSP90α and the Sensitivity and Prognosis of First-Line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
投稿时间:2023-06-10  
DOI:10.13241/j.cnki.pmb.2023.24.028
中文关键词: 晚期非小细胞肺癌  OPN  Wip1  HSP90α  化疗敏感性  预后
英文关键词: Advanced non-small cell lung cancer  OPN  Wip1  HSP90α  Chemotherapy sensitivity  Prognosis
基金项目:河北省医学科学研究课题计划项目(20201185)
作者单位E-mail
朱淑敏 河北医科大学第一医院检验中心 河北 石家庄 050030 15200033993@163.com 
马 进 河北医科大学第三医院检验科 河北 石家庄 050051  
耿玉兰 河北医科大学第一医院检验中心 河北 石家庄 050030  
代丽丽 河北医科大学第一医院检验中心 河北 石家庄 050030  
赵小洁 河北医科大学第一医院检验中心 河北 石家庄 050030  
魏从真 河北医科大学第一医院检验中心 河北 石家庄 050030  
刘金锋 河北医科大学第一医院胸外科 河北 石家庄 050030  
摘要点击次数: 39
全文下载次数: 44
中文摘要:
      摘要 目的:探讨血清骨桥蛋白(OPN)、野生型p53诱导的磷酸酶1(Wip1)、热休克蛋白90α(HSP90α)与晚期非小细胞肺癌(NSCLC)患者一线化疗敏感性和预后的关系。方法:选取2018年1月~2020年1月在河北医科大学附属第一医院接受一线化疗方案治疗的晚期NSCLC患者137例,根据化疗疗效分为化疗不敏感组(38例)和化疗敏感组(99例)。采用酶联免疫吸附法检测血清OPN、HSP90α水平,实时荧光定量聚合酶链式反应检测血清Wip1 mRNA水平。多因素Logistic回归分析影响晚期NSCLC患者一线化疗敏感性的因素。随访3年,Kaplan-Meier法分析高/低血清OPN、Wip1 mRNA、HSP90α水平晚期NSCLC患者一线化疗后的预后情况。结果:与化疗敏感组比较,化疗不敏感组血清OPN、Wip1 mRNA、HSP90α水平升高(P<0.05)。多因素Logistic回归分析显示,低分化、TNM分期Ⅳ期和血清OPN、Wip1 mRNA、HSP90α水平升高为影响晚期NSCLC患者一线化疗敏感性的独立危险因素(P<0.05)。随访3年,137例晚期NSCLC患者总生存率为15.33%(21/137)。Kaplan-Meier生存曲线显示,血清OPN、Wip1 mRNA、HSP90α高水平组3年总生存率低于血清OPN、Wip1 mRNA、HSP90α低水平组(P<0.05)。结论:血清OPN、Wip1、HSP90α水平升高与晚期NSCLC患者一线化疗敏感性下降和预后不良有关。
英文摘要:
      ABSTRACT Objective: To investigate the relationship between serum osteopontin (OPN), wild-type p53-induced phosphatase 1 (Wip1), heat shock protein 90α (HSP90α) and the sensitivity and prognosis of first-line chemotherapy in patients with advanced non-small cell lung cancer(NSCLC). Methods: 137 advanced NSCLC patients who received first-line chemotherapy in the First Affiliated Hospital of Hebei Medical University from January 2018 to January 2020 were selected, patients were divided into chemotherapy insensitive group (38 cases) and chemotherapy sensitive group (99 cases) according to the efficacy of chemotherapy. Serum OPN and HSP90α levels were detected by enzyme-linked immunosorbent assay, and serum Wip1 mRNA level was detected by real-time fluorescence quantitative polymerase chain reaction. The factors affecting the sensitivity of first-line chemotherapy in advanced NSCLC patients were analyzed by multivariate Logistic regression analysis. After 3 years of follow-up, the prognosis of advanced NSCLC patients with high/low serum OPN, Wip1 mRNA and HSP90α levels after first-line chemotherapy were analyzed by Kaplan-Meier method. Results: Compared with chemotherapy sensitive group, the levels of serum OPN, Wip1 mRNA and HSP90α in chemotherapy insensitive group were increased(P<0.05). Multivariate Logistic regression analysis showed that, poor differentiation, TNM stage IV and elevated serum OPN, Wip1 mRNA and HSP90α levels were independent risk factors affecting the sensitivity of first-line chemotherapy in advanced NSCLC patients (P<0.05). After 3 years follow-up, the overall survival rate of 137 advanced NSCLC patients was 15.33% (21/137). Kaplan-Meier survival curve showed that, the 3-year overall survival rate in high-level serum OPN, Wip1 mRNA and HSP90α group was lower than that in low-level serum OPN, Wip1 mRNA and HSP90α group(P<0.05). Conclusion: Serum OPN, Wip1 and HSP90α levels increase are associate with decrease sensitivity to first-line chemotherapy and poor prognosis in advanced NSCLC patients.
查看全文   查看/发表评论  下载PDF阅读器
关闭